HOX Therapeutics is developing innovative therapeutics for prostate cancer for which there is a high unmet medical need.
Prostate cancer is one of the top three most frequently occurring cancers worldwide.
Ten to fifteen percent of patients develop locally recurrent or metastatic disease which is associated with a significantly reduced survival rate.
Prostate cancer has a high rate of mortality.
Epidemiology
Diagnosis and classification
Treatment
Surgery (radical prostatectomy)
Radiotherapy/chemotherapy- DNA damage
Androgen-deprivation therapy (ADT) inhibits androgen signaling
Most patients show initial responses to ADT
A large subset becomes resistant to ADT
The onset of castration-resistant prostate cancer (CRPC)
Read more about metastatic castration-resistant prostate cancer
Hox Therapeutics 